Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review

Rituximab (RTX) is effective for treating cancer, but reports of RTX-associated enterocolitis are limited. We herein report the case of a 65-year-old man who developed RTX-induced ileocolitis. He was diagnosed with gastric mucosa-associated lymphoid tissue lymphoma (MALToma) and treated with RTX. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuzuki, Yoshikazu, Shiomi, Rie, Ashitani, Keigo, Miyaguchi, Kazuya, Osaki, Atsushi, Ohgo, Hideki, Kim, Rei, Sasaki, Atsushi, Yamada, Taketo, Miyakawa, Yoshitaka, Nakamoto, Hidetomo, Imaeda, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990640/
https://www.ncbi.nlm.nih.gov/pubmed/33642561
http://dx.doi.org/10.2169/internalmedicine.5119-20
Descripción
Sumario:Rituximab (RTX) is effective for treating cancer, but reports of RTX-associated enterocolitis are limited. We herein report the case of a 65-year-old man who developed RTX-induced ileocolitis. He was diagnosed with gastric mucosa-associated lymphoid tissue lymphoma (MALToma) and treated with RTX. He complained of bloody diarrhea after RTX. Mucosal inflammation on colonoscopy indicated RTX-induced ileocolitis. He was treated with corticosteroids, and his symptoms improved. We reviewed the RTX-associated gastrointestinal adverse events and classified the features into ulcerative colitis, Crohn's disease, microscopic colitis, and ileocolitis. To our knowledge, this is the first case of a Japanese patient who developed RTX-induced ileocolitis.

Ejemplares similares